Business Context and Reporting Period
Compugen Ltd., a drug and diagnostic discovery company, reported financial results for the first quarter ended March 31, 2005. The company utilizes predictive models and discovery engines to advance biological understanding and develop therapeutic products. The filing is a Form 6-K reporting a press release issued on April 20, 2005.
Key Financial Metrics
| Metric | Q1 2005 | Q1 2004 |
|---|---|---|
| Total Revenues and Grants | $865,000 | $1,520,000 |
| Revenues (Excluding Grants) | $481,000 | $1,119,000 |
| Governmental and Other Grants | $384,000 | $401,000 |
| Net Loss | $3,738,000 | $2,990,000 |
| Net Loss Per Share | ($0.13) | ($0.11) |
| Operating Loss | ($3,799,000) | ($3,543,000) |
| Cash, Cash Equivalents, and Marketable Securities | $43,467,000 | N/A |
| Total Assets | $50,513,000 | N/A |
| Total Liabilities | $4,563,000 | N/A |
Liquidity: As of March 31, 2005, the company held $43.5 million in cash, cash equivalents, and marketable securities. This represents a decrease of $5 million from December 31, 2004.
Material Changes Versus Prior Period
- Revenue Decline: Total revenues and grants decreased by approximately 43% from $1.52 million in Q1 2004 to $865,000 in Q1 2005. Core revenues (excluding grants) dropped significantly from $1.119 million to $481,000.
- Increased Net Loss: The net loss widened by approximately 25% to $3.738 million from $2.99 million in the prior year quarter.
- Expense Structure: Research and development expenses increased to $3.495 million from $2.896 million. Conversely, cost of revenues decreased substantially to $19,000 from $464,000.
- Non-Cash Items: Q1 2005 included a non-cash income of $10,000 for amortization of deferred compensation, whereas Q1 2004 included a non-cash expense of $238,000 for the same item.
Outlook, Commentary, and Risks
Management Commentary: CEO Mor Amitai highlighted accomplishments in expanding discovery capabilities and establishing frameworks for a sustainable discovery company. He noted that the company is making contributions to human therapeutics and diagnostics that are difficult for competitors using traditional methods to achieve.
Forward-Looking Statements: The filing contains forward-looking statements regarding future events and performance. These are subject to risks including changes in collaborator relationships, competitive products, technological changes, product development risks, and the ability to retain customers.
Unusual Items: The filing notes that the larger cash decrease in the most recent quarter ($5 million) compared to the fourth quarter of 2004 ($3.5 million) is related to the timing of certain receipts and expenditures.
Investor Verification Checklist
- Verify the sustainability of the decline in core revenues (excluding grants) from $1.119 million to $481,000.
- Confirm the burn rate and runway based on the $43.5 million cash balance and the $3.7 million quarterly net loss.
- Assess the impact of the significant reduction in cost of revenues on future gross margins.
- Review the status of partnerships with major customers (Abbott, Novartis, Pfizer) given the revenue decline.
- Monitor the progress of the in-house pipeline and out-licensed discoveries mentioned in the business overview.